Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | APEX1 | P27695 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3287063 | 0.99 | HSD17B10 (0.61) | HSD17B10TDP1MEN1KMT2AMAPT | |
| SCHEMBL5447002 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1KMT2AMAPT | |
| SCHEMBL314687 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1KMT2AMAPT | |
| SCHEMBL9609762 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1KMT2AMAPT | |
| SCHEMBL6413992 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1KMT2AMAPT | |
| SCHEMBL1602877 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1KMT2AMAPT | |
| SCHEMBL1603399 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1KMT2AMAPT | |
| SCHEMBL1603405 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1KMT2AMAPT | |
| SCHEMBL1603809 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1KMT2AMAPT | |
| SCHEMBL21051915 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078220-B2 | High-purity large-scale preparation of stannsoporfin | Mallinckrodt Hospital Products IP Limited (IE) | 2021-08-03 | — | — | US | disclosed |
| US-20200255458-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | MALLINCKRODT LLC | 2020-08-13 | — | — | US | disclosed |
| US-10662209-B2 | High-purity large-scale preparation of stannsoporfin | Mallinckrodt Hospital Products IP Limited (IE) | 2020-05-26 | — | — | US | disclosed |
| US-20190201414-A1 | INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202846-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SpecGx LLC | 2019-07-04 | — | — | US | disclosed |
| US-10273255-B2 | High-purity large-scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| CN-104116745-B | composition comprising stannsoporfin | 婴儿护理药品公司 | 2018-07-06 | — | — | CN | disclosed |
| US-20180134735-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | MALLINCKRODT LLC | 2018-05-17 | — | — | US | disclosed |
| US-9902745-B2 | High-purity large-scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORPORATION (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170073362-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | VTESSE LLC | 2017-03-16 | — | — | US | disclosed |
| US-20140005380-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | INFACARE PHARMACEUTICAL CORPORATION (US) | 2014-01-02 | — | — | US | disclosed |
| US-8530458-B2 | High-purity large-scale preparation of stannsoporfin | INFACARE PHARMACEUTICAL CORPORATION (US) | 2013-09-10 | — | — | US | disclosed |
| EP-2086546-B1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2384756-A2 | High-purity large-scale preparation of stannsoporfin | InfaCare Pharmaceutical Corporation (US) | 2011-11-09 | — | — | EP | disclosed |
| US-7960371-B2 | reduction of hemin with hydrogenation catalysts, in the presence of hydrogen, then heating to remove iron and form mesoporphyrin, and reacting with tin oxide top form pure tin mesoporphyrin; inhibitor of heme oxygenase, used in the treatment of infant jaundice or hyperbilirubinemia; liver disorders | INFACARE PHARMACEUTICAL CORPORATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110082292-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | OCERA THERAPEUTICS LLC | 2011-04-07 | — | — | US | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2086546-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | Viamet Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008064311-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080125585-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | STRATATECH CORPORATION | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005380-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | HSD17B10 2207/4885TDP1 3387/4885MEN1 422/4885 |
| US-20180134735-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | HSD17B10 2207/4885TDP1 3387/4885MEN1 422/4885 |
| US-10662209-B2 | High-purity large-scale preparation of stannsoporfin | SNRPF, HNRNPF, NUP188 | HSD17B10 2207/4885TDP1 3387/4885MEN1 422/4885 |
| US-20080125585-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | HSD17B10 2207/4885TDP1 3387/4885MEN1 422/4885 |
| US-10273255-B2 | High-purity large-scale preparation of stannsoporfin | SNRPF, HNRNPF, NUP188 | HSD17B10 2207/4885TDP1 3387/4885MEN1 422/4885 |
| US-20200255458-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | HSD17B10 2207/4885TDP1 3387/4885MEN1 422/4885 |
| US-20190201414-A1 | INHIBITOR OF HEME DEGRADATION FOR USE TO IMPROVE ANTIBIOTIC TREATMENT OF MYCOBACTERIUM TUBERCULOSIS INFECTION | HMOX1, HMOX2, PPOX | HSD17B10 703/4885TDP1 3212/4885MEN1 2939/4885 |
| US-20170073362-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | HSD17B10 2207/4885TDP1 3387/4885MEN1 422/4885 |
| US-11078220-B2 | High-purity large-scale preparation of stannsoporfin | SNRPF, HNRNPF, NUP188 | HSD17B10 2207/4885TDP1 3387/4885MEN1 422/4885 |
| US-20190202846-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | HSD17B10 2207/4885TDP1 3387/4885MEN1 422/4885 |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | HSD17B10 291/4885TDP1 885/4885MEN1 2874/4885 |
| US-20110082292-A1 | HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN | SNRPF, HNRNPF, NUP188 | HSD17B10 2207/4885TDP1 3387/4885MEN1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.